2013 to 2021 Saw Decline in Benzodiazepine Initiation Post-AIS

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 17, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Oct. 17, 2024 -- From 2013 to 2021, there was a decline in benzodiazepine initiation for post-acute ischemic stroke (AIS), according to a study published online Oct. 17 in Stroke.

Victor Lomachinsky Torres, M.D., from Massachusetts General Hospital in Boston, and colleagues analyzed a 20 percent sample of U.S. Medicare claims from April 1, 2013, to Sept. 30, 2021, to examine prescription patterns of benzodiazepines at the national level. Beneficiaries aged 65 years or older discharged alive following an AIS who had traditional Medicare coverage and six months of prior enrollment in Parts A, B, and D were included. Data were analyzed for 126,050 beneficiaries (mean age, 78 years).

The researchers found that 4.9 percent of beneficiaries initiated a benzodiazepine within 90 days. Lorazepam and alprazolam were the most prescribed new prescriptions (40 and 33 percent, respectively). Overall, 76 and 55 percent of first fills had a day's supply over seven days and between 15 and 30 days, respectively. Initiation rates were higher for women than men (5.5 and 3.8 percent, respectively). Rates were highest in the Southeast (5.1 percent) and lowest in the Midwest (4.0 percent). From 2013 to 2021, there was a modest nationwide decline in initiation (cumulative incidence difference, 1.6 percent).

"Despite an overall downward trend of benzodiazepine initiation among AIS survivors, we noted a concerning possible overuse pattern of benzodiazepine prescriptions dispensed to patients within 90 days of discharge," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-18 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords